With the rise of multidrug-resistant bacteria, innovative antimicrobial strategies are needed to treat bacterial infection

In an interview published in ScienceToday, the Dr Johann Mignolet, R&D project manager in the company Syngulon and visitor researcher in the LIBST (Pascal Hols’ lab, BGM), described how we might overhaul small antimicrobial peptides known as bacteriocins to solve bacterial issues.
He also proposed to mobilize the bacteriocin producers naturally dwelling in our gut for therapeutics.

More informations (in french) : Les bactériocines, une alternative aux antibiotiques ?

 

Published on May 15, 2019